Sarepta Therapeutics (SRPT) Net Margin (2010 - 2026)

Sarepta Therapeutics' Net Margin history runs 15 years deep, the most recent figure standing at 45.29% for Q1 2026.

• In Q1 2026, Net Margin rose 38093.0% year-over-year to 45.29%; the TTM figure through Mar 2026 stood at 2.98% (up 1829.0% YoY), while the FY2025 annual figure was 38.27%, down 5064.0% from the prior year.
• Net Margin for Q1 2026 stood at 45.29%, up from 63.87% in the prior quarter.
• The five-year high for Net Margin was 45.29% in Q1 2026, with the low at 335.64% in Q1 2025.
• The 5-year median for Net Margin is 9.16% (2023), against an average of 47.39%.
• The sharpest annual moves came in 2025 and 2026: Net Margin sank 34448 bps in 2025, then surged 38093 bps in 2026.
• Sarepta Therapeutics' Net Margin stood at 38.02% in 2022, then slumped by 89 bps to 4.22% in 2023, then jumped by 472 bps to 24.12% in 2024, then sank by 365 bps to 63.87% in 2025, then soared by 171 bps to 45.29% in 2026.
• Business Quant data shows SRPT's Net Margin at 45.29% in Q1 2026, 63.87% in Q4 2025, and 45.06% in Q3 2025.